Oireachtas Joint and Select Committees
Wednesday, 12 July 2017
Joint Oireachtas Committee on Health
Evaluating Orphan Drugs: Discussion
9:00 am
Professor Michael Barry:
There is a difference between negotiating on price, which I completely agree on, and the assessment process. There are no agencies in some eastern European countries. Germany will not accept the parameters that we would accept in an assessment. We are closer to the UK and Holland. France will not carry out a formal cost effectiveness analysis. Different things go on in different countries, and that makes it difficult from an assessment point of view. On the issue of negotiation on pricing I find it hard to disagree with the Deputy.
No comments